Dr. Reddy's faces revenue slowdown post gRevlimid boost, but new investments and partnerships offer long-term growth ...

Dr. Reddy's Laboratories Ltd has generally positive cash flows and an excellent current ratio of 2.58. Additionally, the ...

Mayur Maheshwari, CEO of UPSIDA, said the Bulk Drug Pharma Park would be important in reducing India's dependence on China ...

Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

The daily Elliott Wave analysis for Dr Reddy Laboratories highlights a bullish trend with current market action in an impulsive phase. Orange wave 3 is unfolding within a broader navy blue wave 1 ...

Investors eye several stocks as the Reserve Bank of India is expected to announce a rate cut, potentially boosting the market ...

Stocks including Bajaj Finserv, IREDA, Coal India, Dr Reddy's Labs, Praj Industries, JSW Energy, SpiceJet, Ashoka Buildcon ...

Indian stock markets are showing signs of recovery. SpiceJet is dealing with an insolvency tribunal matter. JSW Energy has ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

Fintel reports that on June 5, 2025, HSBC upgraded their outlook for Dr. Reddy's Laboratories Limited - Depositary Receipt () ...

Dr. Reddy's Laboratories Ltd marked a 5.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.